Genentech Licenses Prostate Cancer Drug From China-Based Jemincare

 
• By Alaric DeArment
  
Roche's Genentech inked a deal with Jemincare focused on an androgen receptor degrader drug • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Deals

More from Business